guidance on bioequivalence
play

Guidance on bioequivalence Bioavailability, bioequivalence and - PowerPoint PPT Presentation

Guidance on bioequivalence Bioavailability, bioequivalence and biowaiver data summary forms Wenjie Ji and Dr Christopher Crane Pharmaceutical Chemistry Section Scientific Evaluation Branch Medicines Regulation Division, TGA 4 June 2020


  1. Guidance on bioequivalence Bioavailability, bioequivalence and biowaiver data summary forms Wenjie Ji and Dr Christopher Crane Pharmaceutical Chemistry Section Scientific Evaluation Branch Medicines Regulation Division, TGA 4 June 2020

  2. Today’s objectives • Background • How does it help you • How to complete the new forms • Recent updates • Q&A 1

  3. New data summary forms - Published in December 2019 • Bioequivalence study • Additional strength biowaiver • Biopharmaceutics Classification System (BCS)-based biowaiver The forms are: • Non-mandatory • New prescription generic medicine submissions • Currently, we have received completed templates in submissions 2

  4. Background • Using data summary forms – not new concept e.g. Swissmedic, Health Canada, World Health Organization (WHO) and etc • Effects of using these forms – Support for sponsors with respect to meeting technical requirements – Increased efficiency to the evaluation process 3

  5. Background • February 2019 public consultation: Reforms to the generic medicine market authorisation process – Reducing barriers through international alignment – Increased clarity and transparency of regulatory requirements – Supporting work sharing opportunities – Need for a robust supply of medicines in Australia 4

  6. Background • 23 consultation submissions received from medicine industry, industry bodies, health professionals, consumer groups, international technical working group and a statutory authority • Feedback received: strong support for the reform Specifically for the forms: adopting forms  Increase clarity and transparency  Increase international alignment  Increase opportunity for international collaboration  Reduce regulatory burden 5

  7. Design of the forms The new forms were developed based on: • Bioequivalence study information form developed by Australia-Canada- Singapore-Switzerland (ACSS) Consortium – Similar to forms used by Swissmedic, Health Canada, WHO – Most key technical requirements are the same • Biowaiver templates developed by International Pharmaceutical Regulators Programme (IPRP) ≈ – Similar to forms used by WHO – Most key technical requirements are the same 6

  8. Design of the forms • Q&A style format – Better clarify what information to provide – Consistent style – Additional TGA guidance to help complete the forms 7

  9. Greater consistency/reducing burden • Now, accepting completed overseas forms – Bioequivalence study form submitted to  Canada  Singapore  Switzerland – IPRP biowaiver forms submitted to one of our comparable overseas regulator With the condition that: • Your overseas submission has been accepted for evaluation Full details on condition of acceptance is detailed in a guidance prepared for the forms Consequently, you may be using an overseas reference product . 8

  10. Greater consistency/Reducing burden • Existing mandatory requirements – CTD module 1.9.1 - Summary of a Bioavailability or Bioequivalence Study form – CTD module 2.5 – CTD module 2.7 Not required for most new generic prescription medicine submissions • See full details in guidance 9

  11. Difference of new form vs. existing form The new form includes applicant’s section and evaluator’s section Applicant specific sections: Evaluator specific sections: • Data summary • Evaluator comment • Location in the dossier for critical • s31 requests raw data • s31 response assessment • Applicant response to the s31 • Final recommendation on bioequivalence requests 10

  12. Where to find the forms 11

  13. Where to find the forms 12

  14. Guidance to help complete the forms The guidance includes sections on: • When to use the forms • How to include forms for an application • Changes to dossier requirements • How to include overseas forms • How to complete the forms including – additional explanatory notes for some section – example responses Any issues contact PCS inbox: pcsinbox@health.gov.au 13

  15. Recent update to the forms On 1 April, the following forms were updated following external feedback: • Bioequivalence Study Information Form (BSIF): – Removed request under section 2.2 to include information on ‘Recent inspections of the clinical and bioanalytical sites by Regulatory Authorities’ – Guidance updated, where explanatory notes of this part was removed • Additional biowaiver form: – A minor editorial amendment has been made to the assurances in section 3.5.3 14

  16. Questions? 15

Recommend


More recommend